New Active Substance First Launches Rebound In 2017
Executive Summary
2017 was the second-best year for new drug launches worldwide since the start of the millennium, new research by Informa Pharma Intelligence's Pharmaprojects has found.
You may also be interested in...
A Year To Remember For US Drug Launches
A record-breaking 46 novel drugs and biologics were approved by FDA in 2017. The number of drugs that launched were plentiful and several were highly innovative, ushering in a new era of therapeutic breakthroughs. Turning pioneering medicines into commercial successes will be the test.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.